Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.75 -4.0% 42.00 42.00 43.10 42.00 42.00 42.00 161,202 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 12.1 191

Ekf Diagnostics Share Discussion Threads

Showing 4251 to 4270 of 4500 messages
Chat Pages: 180  179  178  177  176  175  174  173  172  171  170  169  Older
DateSubjectAuthorDiscuss
29/4/2022
11:15
Trellus are expected to report their 2021 full year results on 10th May.
jacks13
29/4/2022
07:18
Morning wan - any website changes this early morning to note?
tongosti
28/4/2022
14:42
You've lost your shirt in peace sharw. Top man.
tongosti
28/4/2022
12:03
wan and Drew - please do what the rest of us did long ago then all you will see is:

tongosti 28 Apr '22 - 11:06 - 2682 of 2687 (Filtered)

tongosti 28 Apr '22 - 11:12 - 2683 of 2687 (Filtered)

and this board will be less cluttered

sharw
28/4/2022
11:37
Back to what matters chaps - refreshing the website doesn't seem to have done anything. Mr Market nonplussed - strange that.
tongosti
28/4/2022
10:57
i rest my case


ta

(probably bullied poor chap)

drew lonmenob
28/4/2022
10:51
Of course you do agree sweetheart - cold hard facts are what they are. PS. your opinions re someone's personality are hardly relevant don't you think? Keep it factual dear. Lol
tongosti
28/4/2022
10:12
Btw old chap - the only thing you can take to the shop when you go buy a car (or whatever) is cold hard cash not words.

I keep the share price you keep your daily broken record (which has clearly failed over the last decade and you have zilch to show for it), thank you.

Please keep up with the comedy show.

Wish you better luck between now and 2050.

tongosti
28/4/2022
10:06
One feels for our dear wan's ... how to best describe it ... naivite :)10 years of massive underperformance not long enough for our old chap here? LOL
tongosti
28/4/2022
09:42
I am not going to rise to being ridiculed etc, especially when my investment horizons and rationale are clearly very different.

EKF was in fact trading at around these levels in share price terms for all of 2019 and the early part of 2020, but that was before the pandemic, and before the current level of investment and implementation of EKF's Growth Strategy.

So, EKF have been pared back in share price terms, to pre-pandemic when the growth prospects were different (not bad), but arguably the non-COVID prospects, new skills, and new customers, are not comparable to the pre-pandemic period. But unless you take a longer term view, then the share price is all you have to talk about!

wan
28/4/2022
08:42
While wan the good man concerns himself with webpage refreshes and is in the business of denying reality, it might be a good idea to compare the 0% return EKF has posted over the last 10 years against the +220% equivalent posted by SP500. Huge opportunity cost ain't it. Goes to show why passive trackers are Joe's best friend. Dabbling in individual shares clearly is not for everybody.
tongosti
28/4/2022
07:33
EKF's website has undergone a refresh -

hTTps://www.ekfdiagnostics.com/

Two pages particularly caught my attention, Contract Manufacturing -

Antibody testing and Molecular Transport Media
The COVID-19 pandemic has changed the way we interact as individuals and changed the face of medicine and diagnostics - possibly forever.

The demand for fast-turnaround molecular testing has grown exponentially as has the need for result accuracy. Faster and more accurate testing, along with a vaccine, are the paths that lead the world back to work, education and to socialise as we did pre-pandemic.

EKF Diagnostics is working with some of the world's leading epidemiology organisations to manufacture and distribute tests and kits that will ensure communities can get back to normal as quickly and as safely as possible.
hTTps://www.ekfdiagnostics.com/contract-manufacturing.html

And Life Sciences, which highlights the increase in capacity -

In 2022 a 14,500 liter stainless steel fermenter and 8,000 liter media preparation system were added to accommodate bulk orders.
hTTps://www.ekfdiagnostics.com/life-sciences.html

wan
27/4/2022
15:55
Share price moving at the speed of light it seems. Using todays closing price, this level was first seen in the distant Oct 2012. A decade-long progress undone in only a few short months. Wan - what's the latest call on the "fundamentally-driven aka nothing to worry about" front pal?
tongosti
27/4/2022
12:19
For those among you who are curious enough - current price levels were first seen in March 2014. Wan my good man - any idea why this "phenomenal growth" story is trading at a level seen 8 years ago?! All ears pal.
tongosti
25/4/2022
09:22
EKF's Annual Report has been published and I note that, amongst other, that in September 2021 Mr Salter was granted a cash settled share based incentive award, replacing his previous scheme. The award vests if a controlling interest in the Company is acquired by a third party at any time.

Details of the updated terms are disclosed in Note 31, page 76 -

The award vests if a controlling interest in the Company is acquired by a third party at any time while the holder remains an employee. There is a minimum price level below which no amount is payable, of per share with the amount payable being 2.5% of the excess sale price above 70p per share. The fair value of this award has been calculated at £3,296,000 (2020:£nil), using a modified form of a Black Scholes model. The key assumptions in the model include expected volatility of 45%, a risk free rate of 0.69%, and an expected dividend yield of 1.1p per share. There is an assumed acquisition premium and option life.

hTTps://www.ekfdiagnostics.com/res/Annual-report-2021-Digital.pdf

wan
25/4/2022
08:42
Cosmologist - a meteor is approaching Earth at 5x the speed of soundWan - I note peak bearishness so the future is bright for the stock market LOL
tongosti
23/4/2022
08:53
Staying with the theme of how healthcare is changing in terms of delivery, as per my post 2653 (plus posts 2666 and 2667), including why I suggested it's also worth watching Amazon.

It would appear that Amazon is further emerging out of stealth mode and piloting phase etc. In short, Amazon is changing the way healthcare is accessed and delivered by bringing accessible healthcare to the patient, which can also include whilst at work and "at-home follow-up care for labs, tests, and treatment", and is the complete reverse to the usual pattern of the patient to the healthcare/doctor.

I note that the Amazon Care website has been populated further and there are now recent video's which are insightful and also demonstrates that Amazon is indeed changing the way healthcare is delivered -

Healthcare made easy Video at top of website page, and scroll down for 'Meet The Team' video - hTTps://amazon.care/

Plus, Amazon Care for employers "care reimagined" - hTTps://amazon.care/for-employers

Amazon Care is also exhibiting at the huge American Telemedicine Association's 26th Annual Conference & Expo May 1-3 2022 -

About Amazon Care
Amazon Care combines the best of virtual and in-person care to deliver a patient-centric experience. Patients can use the Amazon Care app to access on-demand urgent and primary care via in-app messaging and video; and when in-person care is needed, a nurse can be dispatched to a patient’s home.

hTTps://gotelehealth.live/8_0/exhibitor/exhibitor-details.cfm?exhid=320

ATA2022 Conference & Expo
MISSION
ATA2022 – ATA’s 26th Annual Conference & Expo – is the world’s largest telehealth innovation event. It’s where providers, technology developers, business professionals and leaders from across the healthcare sector convene to have an in-depth, thoughtful, critical discussion about the future of health.
hTTps://gotelehealth.org/ata-2022/

wan
22/4/2022
06:59
Large diagnostic companies have started their quarterly reporting in the US, with most now reporting core revenues on the basis that exclude COVID-19 testing.

COVID-19 testing demand reduced, but with Quest Diagnostics raising the lower end of its COVID-19 testing revenue guidance for full year 2022 to between $850 million and $1 billion. Overall, there is expectation for continuing demand for COVID-19 testing for the remainder of 2022 and into 2023 as the pandemic moves toward an endemic state.

Overall the underlying backdrop is one of recovery and strong growth from the their core businesses (excluding COVID-19 testing), commitments for continued and further investment in their core businesses, with core revenue growth for the full year in the high-single digit percent range.

wan
20/4/2022
11:51
If our wan was a company manager and he would be this blissful (as if nothing had happened to the share price) about it all - when he faces his investors - the very least one could say is that investors would be nonplussed with him. Lol. In reality, they would have probably kicked him out ages ago and leave him to his blissful delusions.
tongosti
20/4/2022
07:52
I would add to the above, that I think online pharmacy and in-person care at patients’ homes will also feature. So, we may see very interesting combined offerings of being closer and very close to the patient, offering both the ordering online of self-testing as well as sample collection (and shipping for certain lab tests), convenient healthcare and in-person diagnostic testing in the home, as well as availability at physical brick-and-mortar pharmacies, including in-store such as Target and Walmart's model. So perhaps Whole Foods (owned by Amazon) will follow this model too, delivering the same and more in terms of offering and indeed delivering another degree of convenient patient interaction, reassurance and care etc.
wan
Chat Pages: 180  179  178  177  176  175  174  173  172  171  170  169  Older
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221130 05:10:05